Woei-A-Jin F J Sherida H, Tesselaar Margot E T, Garcia Rodriguez Patrica, Romijn Fred P H T M, Bertina Rogier M, Osanto Susanne
Department of Clinical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 Leiden, The Netherlands.
Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Centre, Albinusdreef 2, 2333 Leiden, The Netherlands.
Br J Cancer. 2016 Jul 26;115(3):332-8. doi: 10.1038/bjc.2016.170. Epub 2016 Jul 12.
Cancer-related venous thromboembolism (VTE) heralds a poor prognosis, especially in pancreatic adenocarcinoma (PAC). Tissue factor (TF) is implicated as one of the main culprits in PAC-associated VTE and disease progression.
In a prospective cohort study of 79 PAC patients, we measured plasma CA19-9 and microparticle-associated TF activity (MP-TF activity). In addition, we enumerated TF(+)MPs and MUC1(+)MPs in plasma (n=55), and studied the expression of TF, MUC1, CD31 and CD68 in tumour tissue (n=44).
Plasma MP-TF activity was markedly elevated in PAC patients with VTE compared with those without (median: 1925 vs 113 fM Xa min(-1); P<0.001) and correlated with the extent of thromboembolic events, metastatic disease and short survival. Similar results were found for CA19-9. Patients with massively progressing thrombosis and cerebral embolisms despite anticoagulant therapy (n=3) had the highest MP-TF activities (12 118-40 188 fM Xa min(-1)) and CA19-9 (40 730-197 000 kU l(-1)). All tumours expressed MUC1 and TF. MP-TF activity did not correlate with intensity of TF expression in adenocarcinoma cells, but corresponded with numbers of TF(+) macrophages in the surrounding stroma.
Circulating TF(+)MPs and mucins may concertedly aggravate coagulopathy in PAC. Understanding of underlying mechanisms may result in new treatment strategies for VTE prevention and improvement of survival.
癌症相关静脉血栓栓塞(VTE)预示着预后不良,尤其是在胰腺腺癌(PAC)中。组织因子(TF)被认为是PAC相关VTE和疾病进展的主要元凶之一。
在一项对79例PAC患者的前瞻性队列研究中,我们测量了血浆CA19-9和微粒相关TF活性(MP-TF活性)。此外,我们对血浆中TF(+) MPs和MUC1(+) MPs进行了计数(n = 55),并研究了肿瘤组织中TF、MUC1、CD31和CD68的表达(n = 44)。
与无VTE的PAC患者相比,有VTE的PAC患者血浆MP-TF活性显著升高(中位数:1925 vs 113 fM Xa min(-1);P < 0.001),且与血栓栓塞事件的严重程度、转移性疾病和短生存期相关。CA19-9也有类似结果。尽管接受了抗凝治疗,但仍发生大量进展性血栓形成和脑栓塞的患者(n = 3)具有最高的MP-TF活性(12 118 - 40 188 fM Xa min(-1))和CA19-9(40 730 - 197 000 kU l(-1))。所有肿瘤均表达MUC1和TF。MP-TF活性与腺癌细胞中TF表达强度无关,但与周围基质中TF(+)巨噬细胞数量相关。
循环中的TF(+) MPs和粘蛋白可能协同加重PAC中的凝血病。对潜在机制的了解可能会带来预防VTE和改善生存的新治疗策略。